Gain Therapeutics' GT-02287 shows promise in treating Parkinson's disease, with positive results and potential for market ...

The Company has received approval to begin enrollment of the Phase 1b clinical trial in AustraliaPhase 1b clinical trial will assess safety and ...

Gain will be working with local Parkinson’s disease (PD) advocacy groups to support enrollment and expects enrollment to complete in the spring of 2025 with data from the study expected mid-2025.

Idiopathic Parkinson’s disease (IPD) is a central nervous system disorder affecting the basal ganglia that is caused by death of dopamine-producing cells in the substantia nigra. Although IPD is ...

Department of Neuropathology, National Hospitals for Nervous Diseases, London, UK. The Lewy body is a distinctive neuronal inclusion that is always found in the substantia nigra and other specific ...

Human Amniotic Epithelial Stem Cells is under clinical development by iCELL Biotechnology and currently in Phase I for Parkinson's Disease.

Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after administration of GT-02287, suggests that GT-02287 may have the potential to ...

Parkinson's disease is characterized by a collection of uniquely distinguishing symptoms that affect movement and a number of other aspects of daily life. These include, but are not limited to, ...

Dec. 18, 2024 — Dancing lowers the depression associated with Parkinson's disease, and the benefits can be seen in multiple ways, a new study ... Nov. 19, 2024 — A recently published study ...